• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara launches Global Quantitative Systems Pharmacology Consortium

Certara launches Global Quantitative Systems Pharmacology Consortium

January 25, 2017
CenterWatch Staff

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, is launching a Quantitative Systems Pharmacology (QSP) Immunogenicity Consortium. Modeled after Certara’s Simcyp Consortium, and believed to be the first of its kind, the QSP Immunogenicity Consortium brings together biopharmaceutical companies in a pre-competitive environment to cooperatively develop an Immunogenicity Simulator that will predict immunogenicity of biologics and its impact on their pharmacokinetics, efficacy and safety in diverse patient populations.

Immunogenicity is defined by the FDA as the propensity of the therapeutic protein product to generate immune responses to itself and to related proteins or to induce immunologically-related adverse clinical events. In a recent FDA review of 121 approved biological products, 89% of them had immunogenicity reported and in 49% of cases it impacted efficacy. Immunogenicity is especially concerning for vulnerable populations with compromised immune systems, oftentimes the exact cohort receiving the biologic treatment.

“Clients rely on Simcyp to research and provide cutting-edge solutions to understand and manage complex physiological drug reactions. Just as sponsors now use mechanistic physiologically-based pharmacokinetic (PBPK) modeling and simulation via the Simcyp Simulator to manage drug-drug interactions (DDIs) and dosing for special populations, they will be able to use these new QSP models to manage immune responses,” said Simcyp President and Managing Director Steve Toon, Ph.D. “Our models and software tools will enable sponsors to manage immunogenicity by adjusting the biologic dose, route of administration, patient population and/or co-medications. It may also be possible to moderate the immune system’s tolerance of the drug.”

“As immunogenicity to treatment is such a complex process, we need both QSP and mechanistic models of the humoral and cellular responses involved to fully understand it,” said Professor Piet van der Graaf, PharmD, Ph.D., vice president and head of Certara QSP. “Current immunogenicity modeling uses machine learning to predict immunogenicity directly from the biologic drug’s genetic sequence. This is insufficient because it doesn’t account for the full complexity and dynamics of potential physiological responses or the differences between patient populations.”

“We will use a variety of structural, in vitro and in vivo input parameters for our dynamic models, which will be implemented in a robust IT platform coupled to a virtual patient simulator that can be used to make development and regulatory decisions,” added Professor van der Graaf.

Most of the top-40 pharmaceutical companies (including all of the top 10), along with the major regulatory bodies are members of the Simcyp Consortium, which uses Certara’s Simcyp Simulator PBPK modeling and simulation platform to select the most appropriate drug doses, design optimal clinical trials, evaluate new drug formulations, and predict DDIs and PK outcomes in clinical populations. Simcyp Simulator models are used extensively to inform drug label claims.

Mechanistic modeling of PK is now an expected component in regulatory submissions and it is anticipated that QSP modeling will become a requirement as well.

Certara’s Immunogenicity Simulator will help inform the clinical development for biologicals by allowing sponsors to explore optimal dosing routes and regimens, and answer ‘what-if’ questions in virtual patient populations.

Biologics currently comprise one third of all new drug approvals by the FDA. By 2019, they are predicted to generate $445 billion of sales revenue.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing